Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-004239
Filing Date
2025-02-14
Accepted
2025-02-14 18:10:58
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 15129
2 JOINT FILING AGREEMENT ex-99-02142025_110257.htm EX-99.1 6891
  Complete submission text file 0001415889-25-004239.txt   23833
Mailing Address 100 CARDINAL WAY REDWOOD CITY CA 94063
Business Address 100 CARDINAL WAY REDWOOD CITY CA 94063 (650) 649-1004
Adverum Biotechnologies, Inc. (Subject) CIK: 0001501756 (see all company filings)

EIN.: 205258327 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88266 | Film No.: 25631586
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036
Business Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036 212-444-4100
Venrock Healthcare Capital Partners III, L.P. (Filed by) CIK: 0001738048 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A